IKT — Inhibikase Therapeutics, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2020-12-23.
Performance
Technicals
Others in Healthcare
Measured signals that fired on IKT
| date | signal | measured base rate |
|---|---|---|
| 2026-05-15 | Institutional holders jumped in a quarter ownership | -0.52% over 21 days · t = -0.38 · n = 1,553 not distinguishable from its control group |
| 2026-05-07 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
| 2026-03-20 | Volume shock without a price move price | -1.33% over 21 days · t = -4.53 · n = 16,432 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-07-30 | BERMAN DENNIS N Director | Option exercise | 21.9K | 1.26 | 27.5K |
| 2026-07-29 | RA Capital Healthcare Fund LP 10% owner | Other Acquisition/Disposition | 18.0M | — | — |
| 2026-07-29 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Other Acquisition/Disposition | 18.0M | — | — |
| 2026-07-29 | Kolchinsky Peter 10% owner | Other Acquisition/Disposition | 18.0M | — | — |
| 2026-07-29 | Shah Rajeev M. 10% owner | Other Acquisition/Disposition | 18.0M | — | — |
| 2026-02-21 | Aurentz Vincent Director | Disposition to issuer | 255.3K | 0.00 | 0 |
| 2026-02-21 | Munshi Amit Director | Disposition to issuer | 19.1K | 0.00 | 0 |
| 2026-02-21 | Cabell Christopher President & Head of R&D | Disposition to issuer | 338.3K | 0.00 | 0 |
| 2025-11-21 | Sands Capital Alternatives, LLC | Open-market purchase | 2.1M | 1.45 | 3.0M |
| 2025-11-21 | SANDS FRANK M. | Open-market purchase | 2.1M | 1.45 | 3.0M |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Sands Capital Alternatives, LLC | 21.9M | 13.0M |
| Soleus Capital Management, L.P. | 18.3M | 10.9M |
| Fairmount Funds Management LLC | 14.5M | 8.6M |
| Trails Edge Capital Partners, LP | 13.5M | 8.1M |
| ADAR1 Capital Management, LLC | 11.1M | 6.6M |
| Kalehua Capital Management LLC | 10.9M | 6.5M |
| BlackRock, Inc. | 10.6M | 6.3M |
| Blackstone Inc. | 10.0M | 5.9M |
| Siren, L.L.C. | 9.8M | 5.8M |
| Commodore Capital LP | 9.1M | 5.4M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Inhibikase Therapeutics GAAP EPS of -$0.11 in-line · 2026-08-11
- Inhibikase Therapeutics, Inc. (IKT) filed form 8-K · 2026-08-11 · SEC EDGAR
Ask the AI about IKT
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →